IL274702B2 - Compounds and methods for neurological diseases - Google Patents

Compounds and methods for neurological diseases

Info

Publication number
IL274702B2
IL274702B2 IL274702A IL27470220A IL274702B2 IL 274702 B2 IL274702 B2 IL 274702B2 IL 274702 A IL274702 A IL 274702A IL 27470220 A IL27470220 A IL 27470220A IL 274702 B2 IL274702 B2 IL 274702B2
Authority
IL
Israel
Prior art keywords
receptor
seq
engineered
pain
ligand
Prior art date
Application number
IL274702A
Other languages
English (en)
Hebrew (he)
Other versions
IL274702B1 (en
IL274702A (en
Inventor
Kenneth P Greenberg
Orion Keifer Jr
Stefanie Makinson
Anthony Lau
Original Assignee
Coda Biotherapeutics Inc
Coda Assignment For The Benefit Of Creditors Llc
Trames Bio Inc
Kenneth P Greenberg
Orion Keifer Jr
Stefanie Makinson
Anthony Lau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Biotherapeutics Inc, Coda Assignment For The Benefit Of Creditors Llc, Trames Bio Inc, Kenneth P Greenberg, Orion Keifer Jr, Stefanie Makinson, Anthony Lau filed Critical Coda Biotherapeutics Inc
Publication of IL274702A publication Critical patent/IL274702A/en
Publication of IL274702B1 publication Critical patent/IL274702B1/en
Publication of IL274702B2 publication Critical patent/IL274702B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL274702A 2017-11-27 2018-11-27 Compounds and methods for neurological diseases IL274702B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590911P 2017-11-27 2017-11-27
US201862659911P 2018-04-19 2018-04-19
PCT/US2018/062575 WO2019104307A1 (en) 2017-11-27 2018-11-27 Compositions and methods for neurological diseases

Publications (3)

Publication Number Publication Date
IL274702A IL274702A (en) 2020-06-30
IL274702B1 IL274702B1 (en) 2025-12-01
IL274702B2 true IL274702B2 (en) 2026-04-01

Family

ID=66632192

Family Applications (2)

Application Number Title Priority Date Filing Date
IL274702A IL274702B2 (en) 2017-11-27 2018-11-27 Compounds and methods for neurological diseases
IL324810A IL324810A (en) 2017-11-27 2025-11-19 Compounds and methods for neurological diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL324810A IL324810A (en) 2017-11-27 2025-11-19 Compounds and methods for neurological diseases

Country Status (12)

Country Link
US (2) US10538571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3716990A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021503960A (cg-RX-API-DMAC7.html)
KR (2) KR20200112811A (cg-RX-API-DMAC7.html)
CN (1) CN111741760A (cg-RX-API-DMAC7.html)
AU (2) AU2018373279B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082907A1 (cg-RX-API-DMAC7.html)
IL (2) IL274702B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020005470A (cg-RX-API-DMAC7.html)
SG (1) SG11202004488TA (cg-RX-API-DMAC7.html)
WO (1) WO2019104307A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408862B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法
US20230102192A1 (en) * 2020-02-20 2023-03-30 The Regents Of The University Of California Therapies for the treatment of diseases and disorders associated with abnormal expression of a neural-associated gene
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2022067044A1 (en) * 2020-09-25 2022-03-31 The Regents Of The University Of California Compositions and methods for ameliorating medical conditions
JP2024505197A (ja) * 2021-01-25 2024-02-05 トレイムス バイオ, インコーポレイテッド 焦点てんかんおよび神経因性疼痛を処置するためのアデノ随伴ウイルスカプシドおよび操作されたリガンド依存性イオンチャネル
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN113730809B (zh) * 2021-10-09 2024-08-16 科悦医疗(苏州)有限公司 一种非侵入式迷走神经联合骶神经刺激装置
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
CN119343455A (zh) * 2022-01-31 2025-01-21 特拉梅斯生物股份有限公司 用于治疗癫痫和神经性疼痛的表达盒
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
AU2023222147A1 (en) * 2022-02-18 2024-09-12 Trames Bio, Inc. Compositions and methods for neurological diseases
WO2025015092A1 (en) * 2023-07-10 2025-01-16 Kriya Therapeutics, Inc. Novel cam-kinase promoter and uses thereof for treating nervous system disorders
CN121866054A (zh) * 2023-08-16 2026-04-14 拜尔吉生物股份有限公司 用于治疗癫痫发作的方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170190758A1 (en) * 2012-12-10 2017-07-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered receptors and their use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3628691B2 (ja) * 1993-03-08 2005-03-16 メルク エンド カンパニー インコーポレーテッド ヒト神経細胞性ニコチン性アセチルコリン受容体組成物およびそれらの使用方法
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
WO1997035478A1 (en) 1996-03-26 1997-10-02 The Regents Of The University Of California Selective target cell activation by expression of a g protein-coupled receptor activated superiorly by synthetic ligand
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2001257378A1 (en) 2000-04-29 2001-11-12 Millennium Pharmaceuticals, Inc. 23949 and 32391, human ion channels and uses thereof
US7883846B2 (en) 2002-05-31 2011-02-08 Sloan-Kettering Institute For Cancer Research Heterologous stimulus-gated ion channels and methods of using same
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
US10682424B2 (en) 2015-03-31 2020-06-16 New York University Compositions and method for reducing seizures
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170190758A1 (en) * 2012-12-10 2017-07-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered receptors and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TILLMAN, TOMMY S., ET AL., ELIC-ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR (?7NACHR) CHIMERAS REVEAL A PROMINENT ROLE OF THE EXTRACELLULAR-TRANSMEMBRANE DOMAIN INTERFACE IN ALLOSTERIC MODULATION., 16 May 2014 (2014-05-16) *

Also Published As

Publication number Publication date
US20190161529A1 (en) 2019-05-30
WO2019104307A1 (en) 2019-05-31
AU2018373279A1 (en) 2020-06-04
CN111741760A (zh) 2020-10-02
SG11202004488TA (en) 2020-06-29
EP3716990A1 (en) 2020-10-07
KR20200112811A (ko) 2020-10-05
JP2024160218A (ja) 2024-11-13
ZA202408862B (en) 2026-01-28
IL274702B1 (en) 2025-12-01
AU2018373279B2 (en) 2024-07-25
JP2021503960A (ja) 2021-02-15
EP3716990A4 (en) 2021-12-08
CA3082907A1 (en) 2019-05-31
IL324810A (en) 2026-01-01
IL274702A (en) 2020-06-30
AU2024227560A1 (en) 2024-11-14
US20210061873A1 (en) 2021-03-04
MX2024014448A (es) 2024-12-06
KR20260030128A (ko) 2026-03-05
MX2020005470A (es) 2020-11-09
US10538571B2 (en) 2020-01-21
AU2024227560B2 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
IL274702A (en) Compounds and Methods for Neurological Diseases
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
GB201706751D0 (en) Compositions and methods for treating inflamatory diseases
GB201914076D0 (en) Methods and compositions for enhancing health
IL246791A0 (en) Compositions and methods for treating eye diseases
SG11201706755SA (en) Methods and compositions for treating genetic eye diseases
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3310385A4 (en) Methods and compositions for treating fibrotic diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
IL274524A (en) Preparations and methods for aquaculture
IL270114B1 (en) Methods and compounds for the treatment of neurological diseases
IL272937A (en) Preparations and methods for the treatment of diseases involving fibrosis
IL258139A (en) Nicotine compositions and methods for their preparation and use
SG11201704829QA (en) Methods and compositions for treating brain diseases
ZA201907238B (en) Compositions for treating neurodegenerative diseases
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3107534A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3672583A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
IL252707B (en) Compositions and methods for treating diseases
HK40038636A (en) Compositions and methods for neurological diseases
GB201603510D0 (en) Compositions for use in the treatment of neurological disease